Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

Benzer Materyaller

• Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
  Yazar:: London, Cheryl A., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro
  Yazar:: Jorquera, Patricia A., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
  Yazar:: Breit, Megan N, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines
  Yazar:: Breitbach, Justin T., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
  Yazar:: Yoko Tabe, ve diğerleri
  Baskı/Yayın Bilgisi: (2015-01-01)